Press Releases - Cardiol Therapeutics

Investor Resources

Contact Us

Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

November 5, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units

November 3, 2021

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units

November 2, 2021

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis

October 25, 2021

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx™, into Brazil, Mexico, and Canada

October 18, 2021

Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 16, 2021

Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants issued on June 4, 2020

September 10, 2021

Cardiol Therapeutics Appoints Michael J. Willner to its Board of Directors

September 7, 2021

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis

August 24, 2021